SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy
Abstract
:1. Introduction
2. Methods
2.1. Setting
2.2. Statistical Analysis
3. Results
3.1. Study Population and SARS-CoV-2 Prevalence
3.2. Burden of HIV-Positive Patients and Migrants with COVID-19
3.3. Vaccination Coverage
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
References
- Istituto Superiore Sanità. COVID-19 Integrated Surveillance Data in Italy. Available online: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard (accessed on 25 March 2022).
- Patel, J.A.; Nielsen, F.B.H.; Badiani, A.A.; Assi, S.; Unadkat, V.A.; Patel, B.; Ravindrane, R.; Wardle, H. Poverty, Inequality and COVID-19: The Forgotten Vulnerable. Public Health 2020, 183, 110–111. [Google Scholar] [CrossRef]
- Katzenschlager, S.; Zimmer, A.J.; Gottschalk, C.; Grafeneder, J.; Schmitz, S.; Kraker, S.; Ganslmeier, M.; Muth, A.; Seitel, A.; Maier-Hein, L.; et al. Can We Predict the Severe Course of COVID-19—A Systematic Review and Meta-Analysis of Indicators of Clinical Outcome? PLoS ONE 2021, 16, e0255154. [Google Scholar] [CrossRef] [PubMed]
- Pagani, G.; Conti, F.; Giacomelli, A.; Oreni, L.; Beltrami, M.; Pezzati, L.; Casalini, G.; Rondanin, R.; Prina, A.; Zagari, A.; et al. Differences in the Prevalence of SARS-CoV-2 Infection and Access to Care between Italians and Non-Italians in a Social-Housing Neighbourhood of Milan, Italy. Int. J. Environ. Res. Public Health 2021, 18, 10621. [Google Scholar] [CrossRef] [PubMed]
- Giacomelli, A.; Ridolfo, A.L.; Bonazzetti, C.; Oreni, L.; Conti, F.; Pezzati, L.; Siano, M.; Bassoli, C.; Casalini, G.; Schiuma, M.; et al. Mortality among Italians and Immigrants with COVID-19 Hospitalised in Milan, Italy: Data from the Luigi Sacco Hospital Registry. BMC Infect. Dis. 2022, 22, 63. [Google Scholar] [CrossRef] [PubMed]
- ATS Brescia, Banca dati assistiti integrata: Presa in carico nel 2020. Available online: https://www.ats-brescia.it/documents/3432658/8478812/BDA2020B.pdf/45e31d1b-38e8-67f7-35ba-452ed9887a58 (accessed on 25 March 2022).
- Comelli, A.; Izzo, I.; Donato, F.; Celotti, A.; Focà, E.; Pezzoli, C.; Castelli, F.; Quiros-Roldan, E. Disengagement and Reengagement of HIV Continuum of Care in a Single Center Cohort in Northern Italy. HIV Res. Clin. Pract. 2019, 20, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Quiros-Roldan, E.; Magoni, M.; Raffetti, E.; Donato, F.; Scarcella, C.; Paraninfo, G.; Castelli, F. The Burden of Chronic Diseases and Cost-of-Care in Subjects with HIV Infection in a Health District of Northern Italy over a 12-Year Period Compared to That of the General Population. BMC Public Health 2016, 16, 1146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smit, M.; Cassidy, R.; Cozzi-Lepri, A.; Quiros-Roldan, E.; Girardi, E.; Mammone, A.; Antinori, A.; Saracino, A.; Bai, F.; Rusconi, S.; et al. Projections of Non-Communicable Disease and Health Care Costs among HIV-Positive Persons in Italy and the U.S.A.: A Modelling Study. PLoS ONE 2017, 12, e0186638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gasmi, A.; Peana, M.; Pivina, L.; Srinath, S.; Gasmi Benahmed, A.; Semenova, Y.; Menzel, A.; Dadar, M.; Bjørklund, G. Interrelations between COVID-19 and Other Disorders. Clin. Immunol. 2021, 224, 108651. [Google Scholar] [CrossRef] [PubMed]
- Izcovich, A.; Ragusa, M.A.; Tortosa, F.; Lavena Marzio, M.A.; Agnoletti, C.; Bengolea, A.; Ceirano, A.; Espinosa, F.; Saavedra, E.; Sanguine, V.; et al. Prognostic Factors for Severity and Mortality in Patients Infected with COVID-19: A Systematic Review. PLoS ONE 2020, 15, e0241955. [Google Scholar] [CrossRef]
- Kinner, S.A.; Young, J.T.; Snow, K.; Southalan, L.; Lopez-Acuña, D.; Ferreira-Borges, C.; O’Moore, É. Prisons and Custodial Settings Are Part of a Comprehensive Response to COVID-19. Lancet Public Health 2020, 5, e188–e189. [Google Scholar] [CrossRef]
- Wang, G.; Foney, D.M.; DiBari, J.; Hong, X.; Showell, N.; Kim, K.S.; Ji, H.; Pearson, C.; Mirolli, G.; Rusk, S.; et al. A Prospective Cohort Study on the Intersectionality of Obesity, Chronic Disease, Social Factors, and Incident Risk of COVID-19 in US Low-Income Minority Middle-Age Mothers. Int. J. Obes. 2021, 45, 2577–2584. [Google Scholar] [CrossRef]
- Jaljaa, A.; Caminada, S.; Tosti, M.E.; D’Angelo, F.; Angelozzi, A.; Isonne, C.; Marchetti, G.; Mazzalai, E.; Giannini, D.; Turatto, F.; et al. Risk of SARS-CoV-2 Infection in Migrants and Ethnic Minorities Compared with the General Population in the European WHO Region during the First Year of the Pandemic: A Systematic Review. BMC Public Health 2022, 22, 143. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-García-de-Cortázar, A.; Leralta-Piñán, O.; Jiménez-Pernett, J.; Ruiz-Azarola, A. COVID-19 on Migrants and Ethnic Minorities. Gac. Sanit. 2021, 35, 499–501. [Google Scholar] [CrossRef] [PubMed]
- ISTAT, Resident Foreigners on 1st January. Available online: http://dati.istat.it/Index.aspx?lang=en&SubSessionId=b6f57c2e-f8ac-418f-a695-b9384f4bdd4a (accessed on 25 March 2022).
- European Centre for Disease Prevention and Control, Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU/EEA. Available online: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans (accessed on 25 March 2022).
- Italian Ministry of Health, Vaccinazione Anti-SARS-COV 2/COVID 19 Raccomandazioni Ad Interim Sui Gruppi Target Della Vaccinazione. Available online: https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=24/03/2021&redaz=21A01802&artp=1&art=1&subart=1&subart1=10&vers=1&prog=002 (accessed on 25 March 2022).
- Regione Lombardia, Dettaglio Delle Somministrazioni Dei Vaccini in Lombardia. Available online: https://www.regione.lombardia.it/wps/portal/istituzionale/HP/vaccinazionicovid/dashboard-vaccini-territorio (accessed on 25 March 2022).
- Dbouk, T.; Drikakis, D. Correcting Pandemic Data Analysis through Environmental Fluid Dynamics. Phys. Fluids 2021, 33, 067116. [Google Scholar] [CrossRef] [PubMed]
- Boehme, C.; Hannay, E.; Sampath, R. SARS-CoV-2 Testing for Public Health Use: Core Principles and Considerations for Defined Use Settings. Lancet Glob. Health 2021, 9, e247–e249. [Google Scholar] [CrossRef]
- Russo, A.G.; Tunesi, S.; Consolazio, D.; Decarli, A.; Bergamaschi, W. Evaluation of the Anti-COVID-19 Vaccination Campaign in the Metropolitan Area of Milan (Lombardy Region, Northern Italy). Epidemiol. Prev. 2021, 45, 568–579. [Google Scholar] [CrossRef] [PubMed]
- Danwang, C.; Noubiap, J.J.; Robert, A.; Yombi, J.C. Outcomes of Patients with HIV and COVID-19 Co-Infection: A Systematic Review and Meta-Analysis. AIDS Res. Ther. 2022, 19, 3. [Google Scholar] [CrossRef] [PubMed]
- Tesoriero, J.M.; Swain, C.-A.E.; Pierce, J.L.; Zamboni, L.; Wu, M.; Holtgrave, D.R.; Gonzalez, C.J.; Udo, T.; Morne, J.E.; Hart-Malloy, R.; et al. COVID-19 Outcomes Among Persons Living with or without Diagnosed HIV Infection in New York State. JAMA Netw. Open 2021, 4, e2037069. [Google Scholar] [CrossRef] [PubMed]
- Tesoriero, J.M.; Patterson, W.; Daskalakis, D.; Chicoine, J.; Morne, J.; Braunstein, S.; Rajulu, D.T.; Rosenberg, E. Notes from the Field: COVID-19 Vaccination Among Persons Living with Diagnosed HIV Infection—New York, October 2021. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 182–184. [Google Scholar] [CrossRef] [PubMed]
Total | CITIZENSHIP | p | HIV STATUS | p | |||
---|---|---|---|---|---|---|---|
Italian | Foreigner | Positive | Negative | ||||
N (%) | 1,004,210 | 869,718 (86.6%) | 134,492 (13.4%) | 3817 (0.38%) | 1,000,393 (99.62%) | ||
Age, median (p25-p75) | 51.6 (37.6–66.3) | 53.7 (39.6–68.5) | 40.6 (31.5–50.8) | <0.001 | 54 (46.5–58.9) | 51.6 (37.6–66.3) | 0.02 |
Age category | |||||||
18–49 N (%) | 469,586 (46.8%) | 370,599 (42.6%) | 98,987 (73.6%) | <0.001 | 1311 (34.3%) | 468,275 (46.8%) | <0.001 |
50–69 N (%) | 266,510 (26.5%) | 239.088 (27.5%) | 27,422 (20.4%) | 2140 (56.1%) | 264,370 (26.4%) | ||
>70 N (%) | 268,114 (26.7%) | 260,031 (29.9%) | 8083 (6.0%) | 366 (9.6%) | 267,748 (26.8%) | ||
Male, N (%) | 492,625 (49.1%) | 427,237 (49.1%) | 65,388 (48.6%) | 0.001 | 2717 (71.2 %) | 489,908 (49.0%) | <0.001 |
Comorbidity | |||||||
none | 563,589 (56.1%) | 461,536 (53.1%) | 102,053 (76.9%) | <0.001 | 1679(44.0%) | 561,910 (56.2%) | <0.001 |
1 | 196,298 (19.5%) | 175,370 (20.1%) | 20,928 (15.6%) | 933 (24.4%) | 195,365 (19.5%) | ||
2–3 | 173,346 (17.3%) | 163,761 (18.8%) | 9585 (7.1%) | 932 (24.4%) | 172,414 (17.2%) | ||
>3 | 70,977 (7.1%) | 69,051 (8.0%) | 1926 (1.4%) | 273 (7.2%) | 70,704 (7.1%) | ||
Citizenship | |||||||
Italian | - | - | 3284 (86.0%) | 866,434 (86.6%) | n.s. | ||
non-Italian | - | - | 533 (14.0%) | 133,959 (13.4%) | |||
HIV status | - | - | |||||
Positive | 3284 (0.4%) | 533 (0.4%) | n.s. | - | - | ||
Negative | 866,434 (99.6%) | 133,959 (99.6%) | |||||
COVID-19 positive cases | 111,319 (11.1%) | 99,186 (11.4%) | 12,133 (9.0%) | <0.001 | 346 (9.1%) | 110,973 (11.1%) | <0.001 |
Admitted to hospital | 15,588 (1.6%) | 14,374 (1.6%) | 1214 (0.9%) | <0.001 | 59 (1.6%) | 15,529 (1.6%) | n.s. |
Admitted to ICU | 1594 (0.2%) | 1459 (1.5%) | 135 (1.1%) | 0.002 | 5 (1.5%) | 1591 (1.4%) | n.s. |
Death | 4297 (0.4%) | 4239 (4.3%) | 58 (0.5%) | <0.001 | 6 (1.7%) | 4292 (3.9%) | 0.04 |
N (%) of reinfections | 2936 (0.3%) | 2632 (2.7%) | 304 (2.5%) | n.s. | 5 (0.9%) | 2932 (2.7%) | 0.04 |
COVID-19 DIAGNOSIS | OR | 95% CI | p | ||
---|---|---|---|---|---|
Yes | No | ||||
Age category | |||||
18–49 N | 56,982 (51.2%) | 412,604 (46.2%) | 1 reference | ||
50–69 N | 28,731 (25.8%) | 237,779 (26.6%) | 0.80 | 0.79–0.82 | <0.001 |
>70 N | 25,606 (23.0%) | 242,508 (27.2%) | 0.60 | 0.59–0.61 | <0.001 |
Gender | |||||
Female | 56,183 (50.5%) | 455,402 (51.0%) | 1 reference | ||
Male | 55,136 (49.5%) | 437,489 (49.0%) | 1.01 | 0.99–1.02 | n.s |
Comorbidity | |||||
none | 62,339 (56.0%) | 501,250 (56.1%) | 1 reference | ||
1 | 21,370 (19.2%) | 174,928 (19.6%) | 1.09 | 1.07–1.11 | <0.001 |
2–3 | 18,286 (16.4%) | 155,060 (17.4%) | 1.20 | 1.17–1.22 | <0.001 |
>3 | 9324 (8.4%) | 61,653 (6.9%) | 1.67 | 1.63–1.72 | <0.001 |
Citizenship | |||||
Italian | 99,186 (89.1%) | 770,532 (86.3%) | 1 reference | ||
Foreigner | 12,133 (10.9%) | 122,359 (13.7%) | 0.71 | 0.70–0.73 | <0.001 |
HIV status | |||||
negative | 110,973 (99.7%) | 889,420 (99.6%) | 1 reference | ||
positive | 346 (0.3%) | 3471 (0.4%) | 0.77 | 0.69–0.86 | <0.001 |
COVID-19 Cases Admitted to Hospital (Any Department) | OR | 95% CI | p | ||
---|---|---|---|---|---|
Yes | No | ||||
Age category | |||||
18–49 | 1736 (11.1%) | 55,246 (57.7%) | 1 reference | ||
50–69 | 3644 (23.4%) | 25,087 (26.2%) | 3.63 | 3.41–3.86 | <0.001 |
>70 N | 10,208 (65.5%) | 15,398 (16.1%) | 11.30 | 10.58–12.07 | <0.001 |
Sex | |||||
Female | 6456 (41.4%) | 49,727 (51.9%) | 1 reference | ||
Male | 9132 (58.6%) | 46,004 (48.1%) | 1.81 | 1.74–1.88 | <0.001 |
Comorbidity | |||||
none | 2916 (18.7%) | 59,423 (62.1%) | 1 reference | ||
1 | 2863 (18.4%) | 18,507 (19.3%) | 1.83 | 1.73–1.94 | <0.001 |
2–3 | 5489 (35.2%) | 12,797 (13.4%) | 2.94 | 2.78–3.12 | <0.001 |
>3 | 4320 (27.7%) | 5004 (5.2%) | 4.29 | 4.02–4.58 | <0.001 |
Citizenship | |||||
Italian | 14,374 (92.2%) | 84,812 (88.6%) | 1 reference | ||
Foreigner | 1214 (7.8%) | 10,919 (11.4%) | 1.97 | 1.84–2.12 | <0.001 |
HIV status | |||||
negative | 15,529 (99.6%) | 95,444 (99.7%) | 1 reference | ||
positive | 59 (0.4%) | 287 (0.3%) | 1.15 | 0.85–1.56 | n.s |
COVID-19 Cases Admitted to ICU | OR | 95% CI | p | ||
---|---|---|---|---|---|
Yes | No | ||||
Age category | |||||
18–49 N (%) | 157 (9.8%) | 56,825 (51.8%) | 1 reference | ||
50–69 N (%) | 485 (30.4%) | 28,246 (25.7%) | 4.68 | 3.88–5.65 | <0.001 |
>70 N (%) | 954 (59.8%) | 24,652 (22.5%) | 8.43 | 6.91–10.27 | <0.001 |
Sex | |||||
Female | 439 (27.5%) | 55,744 (50.8%) | 1 reference | ||
Male | 1157 (72.5%) | 53,979 (49.2%) | 2.86 | 2.56–3.2 | <0.001 |
Comorbidity | |||||
none | 277 (17.4%) | 62,062 (56.6%) | 1 reference | ||
1 | 382 (23.9%) | 20,988 (19.1%) | 2.48 | 2.11–2.92 | <0.001 |
2–3 | 615 (38.5%) | 17,671 (161%) | 3.03 | 2.58–3.57 | <0.001 |
>3 | 322 (20.2%) | 9002 (8.2%) | 2.53 | 2.1–3.06 | <0.001 |
Citizenship | |||||
Italian | 1461 (91.5%) | 97,725 (89.1%) | 1 reference | ||
Foreigner | 135 (8.5%) | 11,998 (10.9%) | 1.83 | 1.50–2.19 | <0.001 |
HIV status | |||||
negative | 1591 (99.7%) | 109,382 (99.7%) | 1 reference | ||
positive | 5 (0.3%) | 341 (0.3%) | 0.72 | 0.30–1.76 | n.s |
COVID-19 Related Death | OR | 95% CI | p | ||
---|---|---|---|---|---|
Yes | No | ||||
Age category | |||||
18–49 N (%) | 26 (0.6%) | 56,956 (53.2%) | 1 reference | ||
50–69 N (%) | 246 (5.7%) | 28,485 (26.6%) | 12.61 | 8.39–18.95 | <0.001 |
>70 N (%) | 4026 (93.7%) | 21,580 (20.2%) | 164.46 | 110.81–244.09 | <0.001 |
Sex | |||||
Female | 1713 (39.9%) | 54,470 (50.9%) | 1 reference | ||
Male | 2585 (60.1%) | 52,551 (49.1%) | 1.82 | 1.7–1.94 | <0.001 |
Comorbidity | |||||
none | 264 (6.1%) | 62,075 (58.0%) | 1 reference | ||
1 | 573 (13.3%) | 20,797 (19.4%) | 1.96 | 1.68–2.29 | <0.001 |
2–3 | 1705 (39.7%) | 16,581 (15.5%) | 3.12 | 2.71–3.58 | <0.001 |
>3 | 1756 (40.9%) | 7568 (7.1%) | 4.67 | 4.06–5.38 | <0.001 |
Citizenship | |||||
Italian | 4239 (98.6%) | 94,947 (88.7%) | 1 reference | ||
Foreigner | 59 (1.4%) | 12,074 (11.3%) | 0.60 | 0.46–0.78 | <0.001 |
HIV status | |||||
negative | 4292 (99.9%) | 106,681 (99.7%) | 1 reference | ||
positive | 6 (0.1%) | 340 (0.3%) | 0.61 | 0.26–1.41 | n.s |
Total | Foreigners | Total | Italians | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HIV+ | HIV− | p | HIV+ | HIV− | p | |||||||
n | % | n | % | n | % | n | % | |||||
Unvaccinated | 32,372 (25.4%) | 109 | 21.60% | 32,263 | 25.40% | <0.001 | 74,219 (8.7%) | 299 | 9.30% | 73,920 | 8.70% | <0.001 |
1 dose | 5160 (4.0%) | 12 | 2.40% | 5148 | 4.10% | 19,968 (2.3%) | 67 | 2.10% | 19,901 | 2.30% | ||
2 doses | 43,610 (34.2%) | 134 | 26.60% | 43,476 | 34.20% | 157,109 (18.5%) | 516 | 16.10% | 156,593 | 18.50% | ||
3 doses | 46,362 (36.4%) | 249 | 49.40% | 46,113 | 36.30% | 599,891 (70.5%) | 2.317 | 72.40% | 597,574 | 70.50% | ||
Total | 127,504 | 504 | 100.00% | 127,000 | 100.00% | 851,187 | 3199 | 100.00% | 847,988 | 100.00% |
Italians | Foreigners | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
At Least One Dose | OR | 95% CI | p | At Least One Dose | OR | 95% CI | p | |||
Yes | No | Yes | No | |||||||
Age category | ||||||||||
18–49 N (%) | 330,598 (42.5%) | 36,223 (48.8%) | 1 reference | 71,871 (75.5%) | 21,951 (67.8%) | 1 reference | ||||
50–69 N (%) | 217,316 (28.0%) | 19,834 (26.7%) | 0.93 | 0.91–0.94 | <0.001 | 19,277 (20.3%) | 6935 (21.4%) | 1.30 | 1.26–1.34 | <0.001 |
>70 N (%) | 229,054 (29.5%) | 18,162 (24.5%) | 0.94 | 0.92–0.96 | <0.001 | 3984 (4.2%) | 3486 (10.8%) | 3.51 | 3.34–3.7 | <0.001 |
Sex | ||||||||||
Female | 395,501 (50.9%) | 37,856 (51.0%) | 1 reference | 47,969 (50.4%) | 17,718 (54.7%) | 1 reference | ||||
Male | 381,467 (49.1%) | 36,363 (49.0%) | 0.97 | 0.96–0.99 | <0.001 | 47,163 (49.6%) | 14,654 (45.3%) | 0.85 | 0.83–0.88 | <0.001 |
Comorbidity | ||||||||||
none | 410,126 (52.8%) | 46,975 (63.3%) | 1 reference | 71,264 (74.9%) | 25,317 (78.2%) | 1 reference | ||||
1 | 160,425 (20.6%) | 12,665 (17.1%) | 0.70 | 0.69–0.72 | <0.001 | 15,526 (16.3%) | 4441 (13.7%) | 0.70 | 0.67–0.72 | <0.001 |
2–3 | 148,162 (19.1%) | 9877 (13.3%) | 0.60 | 0.59–0.62 | <0.001 | 6943 (7.3%) | 2193 (6.8%) | 0.61 | 0.58–0.65 | <0.001 |
>3 | 58,255 (7.5%) | 4702 (6.3%) | 0.73 | 0.71–0.76 | <0.001 | 1399 (1.5%) | 421 (1.3%) | 0.47 | 0.42–0.52 | <0.001 |
HIV status | ||||||||||
negative | 774,068 (99.6%) | 73,920 (99.6%) | 1 reference | 94,737 (99.6%) | 32,263 (99.7%) | 1 reference | ||||
positive | 2900 (0.4%) | 299 (0.4%) | 1.17 | 1.04–1.32 | 0.01 | 395 (0.4%) | 109 (0.3%) | 0.87 | 0.7–1.08 | n.s |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maifredi, G.; Izzo, I.; Gasparotti, C.; Sileo, C.V.; HIV-CoV Group; Castelli, F.; Quiros-Roldan, E. SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy. Life 2022, 12, 1009. https://doi.org/10.3390/life12071009
Maifredi G, Izzo I, Gasparotti C, Sileo CV, HIV-CoV Group, Castelli F, Quiros-Roldan E. SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy. Life. 2022; 12(7):1009. https://doi.org/10.3390/life12071009
Chicago/Turabian StyleMaifredi, Giovanni, Ilaria Izzo, Cinzia Gasparotti, Claudio Vito Sileo, HIV-CoV Group, Francesco Castelli, and Eugenia Quiros-Roldan. 2022. "SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy" Life 12, no. 7: 1009. https://doi.org/10.3390/life12071009
APA StyleMaifredi, G., Izzo, I., Gasparotti, C., Sileo, C. V., HIV-CoV Group, Castelli, F., & Quiros-Roldan, E. (2022). SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy. Life, 12(7), 1009. https://doi.org/10.3390/life12071009